DE69334066D1 - Impfstoffzusammensetzungen für mukosale Abgabe - Google Patents

Impfstoffzusammensetzungen für mukosale Abgabe

Info

Publication number
DE69334066D1
DE69334066D1 DE69334066T DE69334066T DE69334066D1 DE 69334066 D1 DE69334066 D1 DE 69334066D1 DE 69334066 T DE69334066 T DE 69334066T DE 69334066 T DE69334066 T DE 69334066T DE 69334066 D1 DE69334066 D1 DE 69334066D1
Authority
DE
Germany
Prior art keywords
vaccine compositions
tetanus
mucosal surface
provides
mucosal delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69334066T
Other languages
English (en)
Other versions
DE69334066T2 (de
Inventor
Mark Roberts
Gordon Dougan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medeva Holdings BV
Original Assignee
Medeva Holdings BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medeva Holdings BV filed Critical Medeva Holdings BV
Publication of DE69334066D1 publication Critical patent/DE69334066D1/de
Application granted granted Critical
Publication of DE69334066T2 publication Critical patent/DE69334066T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DE69334066T 1992-04-28 1993-04-28 Impfstoffzusammensetzungen für mukosale Abgabe Expired - Lifetime DE69334066T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929209118A GB9209118D0 (en) 1992-04-28 1992-04-28 Vaccine compositions
GB9209118 1992-04-28

Publications (2)

Publication Number Publication Date
DE69334066D1 true DE69334066D1 (de) 2006-11-09
DE69334066T2 DE69334066T2 (de) 2007-05-03

Family

ID=10714652

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69334066T Expired - Lifetime DE69334066T2 (de) 1992-04-28 1993-04-28 Impfstoffzusammensetzungen für mukosale Abgabe
DE69326948T Expired - Lifetime DE69326948T2 (de) 1992-04-28 1993-04-28 Impfstoffzusammensetzungen fuer mukosale abgabe

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69326948T Expired - Lifetime DE69326948T2 (de) 1992-04-28 1993-04-28 Impfstoffzusammensetzungen fuer mukosale abgabe

Country Status (11)

Country Link
US (1) US6562352B1 (de)
EP (2) EP0937462B1 (de)
AT (2) ATE340589T1 (de)
AU (1) AU4267093A (de)
DE (2) DE69334066T2 (de)
DK (2) DK0639081T3 (de)
ES (2) ES2273391T3 (de)
GB (1) GB9209118D0 (de)
GR (1) GR3032381T3 (de)
PT (2) PT937462E (de)
WO (1) WO1993021950A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197548B1 (en) 1990-04-02 2001-03-06 Medeva Pharma Limited Transformed Pichia expressing the pertactin antigen
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
CA2226392A1 (en) * 1995-07-07 1997-01-30 James S. Moncrief Intranasal vaccination against gastrointestinal disease
GB9611501D0 (en) * 1996-06-03 1996-08-07 Smithkline Beecham Biolog Vaccine compositions
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
EP2168593A1 (de) 1998-09-01 2010-03-31 Merrion Research III Limited Orale impfstoff-zusammensetzung
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
EP1107783B1 (de) * 1998-09-01 2006-04-05 ELAN CORPORATION, Plc Verfahren zur induktion der zellulären immunantwort und parenterale impfstoff-zusammensetzungen dazu
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
GB9923060D0 (en) * 1999-09-29 1999-12-01 Chiron Spa Vaccine
US6651655B1 (en) 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MXPA04004726A (es) * 2001-11-19 2004-07-30 Becton Dickinson Co Composiciones farmaceuticas en forma particulada.
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PL2182983T3 (pl) 2007-07-27 2014-10-31 Janssen Alzheimer Immunotherap Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8516442D0 (en) * 1985-06-28 1985-07-31 Wellcome Found Cloned antigen
JPS632932A (ja) * 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
EP0267998A1 (de) 1986-11-17 1988-05-25 Institut Pasteur Mittel zur Unterstützung gegen Infektion und Vergiftung von Bordetella
GB8910570D0 (en) * 1989-05-08 1989-06-21 Wellcome Found Acellular vaccine
GB8914122D0 (en) * 1989-06-20 1989-08-09 Wellcome Found Polypeptide expression
IT1248735B (it) * 1990-06-21 1995-01-26 Sclavo Spa Vaccini acellulari contro la pertosse
EP0484621A3 (en) * 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
CZ285118B6 (cs) * 1991-03-05 1999-05-12 The Wellcome Foundation Limited Exprese rekombinačních proteinů v oslabených bakteriích
US7532327B2 (en) * 2004-09-17 2009-05-12 Jmar Research, Inc. Systems and methods for detecting scattered light from a particle using illumination incident at an angle

Also Published As

Publication number Publication date
DE69326948T2 (de) 2000-03-16
DK0639081T3 (da) 2000-04-10
EP0639081B1 (de) 1999-11-03
EP0639081A1 (de) 1995-02-22
GB9209118D0 (en) 1992-06-10
GR3032381T3 (en) 2000-04-27
WO1993021950A1 (en) 1993-11-11
ATE186218T1 (de) 1999-11-15
DK0937462T3 (da) 2007-01-29
PT639081E (pt) 2000-04-28
ES2273391T3 (es) 2007-05-01
DE69334066T2 (de) 2007-05-03
EP0937462A1 (de) 1999-08-25
DE69326948D1 (de) 1999-12-09
AU4267093A (en) 1993-11-29
PT937462E (pt) 2007-01-31
ATE340589T1 (de) 2006-10-15
EP0937462B1 (de) 2006-09-27
ES2141765T3 (es) 2000-04-01
US6562352B1 (en) 2003-05-13

Similar Documents

Publication Publication Date Title
ATE340589T1 (de) Impfstoffzusammensetzungen für mukosale abgabe
JP3911058B2 (ja) ストレプトコックス エキワクチン
FR16C0015I2 (fr) Vaccins anticoquelucheux acellulaires et procedes de preparation correspondants
FI101632B1 (fi) Menetelmä Bordetella pertussis-toksiinin alayksikön analogien valmistamiseksi ja niitä koodaavia rekombinantti-DNA-molekyylejä
LU90203I2 (fr) Anatoxine diphtérique anatoxine tétanique trois antigènes coquelucheux purifiés (toxine pertussique tp hémagglutinine filamenteuse (haf) et pertactine (protéine de membrane externe 69 kd) et le principal antigène de surface du virus de l'hépatite b (vhb) purfié (infanrix hepb) et ses dérivés pharmaceutiquement acceptables
Podda et al. Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa
FI924457A (fi) Kompositioner och behandlingsfoerfarande foer lunginflammation i djur
Roberts et al. Recombinant P. 69/pertactin: immunogenicity and protection of mice against Bordetella pertussis infection
AU725137B2 (en) Bordetella strain expressing the hybrid FHA, liposomes and vaccines
DK0725653T3 (da) Vaccinepræparater
EP1123711B1 (de) Attenuierte Toxine als Adjuvantien
CA2386023A1 (en) Mucosal dtpa vaccines
PT94030B (pt) Processo de preparacao de antigenios protectores contra as infeccoes e efeitos toxidos de bordetella
JPH02149529A (ja) 百日咳毒素のトキソイド化法
ATE258445T1 (de) Impfstoff beinhaltend bacterin und toxoid aus pasteurella haemolytica typ a-1
DK0623170T3 (da) Vacciner baseret på streptokinase
RU2185852C1 (ru) Способ вакцинопрофилактики дифтерии и столбняка на крайнем севере
Wells et al. Experimental assessment of parainfluenza type 3 virus vaccines

Legal Events

Date Code Title Description
8364 No opposition during term of opposition